General Information
Revision date
2025-11-13
Product name
Fluvoxamine Maleate Extended-Release Capsules
1.2.1 Relevant identified uses
Pharmaceutical drug product used in the treatment of Obsessive-compulsive disorder and social anxiety disorder
Manufacturer Name
Annora Pharma Private Limited
Icons in SDS
Company Information
company name
Annora Pharma Private Limited
Section 2
SECTION 2: Hazards identification
Ingredients CAS Fluvoxamine Maleate 61718-82-9 Sugar Spheres 92004-84-7 Hydroxypropyl Cellulose 9004-64-2 Talc 14807-96-6 Ethyl cellulose 9004-57-3 Triethyl Citrate 77-93-0 Isopropyl alcohol 67-63-0 Dichloromethane 75-09-2 Gelatin 9000-70-8. Titanium Dioxide 13463-67-7 FD&C Blue 1 3844-45-9 Ferric Oxide Yellow 51274-00-1 SLS 151-21-3 Shellac 9000-59-3 Dehydrated Alcohol 64-17-5 Butyl Alcohol 71-36-3 Propylene Glycol 57-55-6 Strong Ammonia Solution 1336-21-6 Black Iron oxide 12227-89-3 Potassium Hydroxide 1310-58-3 Section 3: Health hazards information Potential Health Effects Inhalation: Not expected to be hazardous in final pharmaceutical form. Eye Contact: Not expected to be hazardous in final pharmaceutical form. Skin Contact: Not expected to be hazardous in final pharmaceutical form. Ingestion: Health injuries are not known or expected under normal use. Exposures above clinical dosage could result in adverse effects. Minor occupational exposures are not expected to be harmful. Other: None Effects of Overexposure The potential for exposure is reduced in finished pharma- ceutical form.
